Server was unable to process request. ---> The data types ntext and varchar are incompatible in the equal to operator. Incorrect syntax near ')'. Incorrect syntax near the keyword 'declare'. Khandwala Securities Limited.
NIFTY
41.95  0.42%
 9915.25
S&P BSE SENSEX
124.49  0.39%
 32028.89
Cadila Healthcare Ltd.
NSE : CADILAHC BSE : 532321 ISIN code : INE010B01027
on 21-Jul-2017
NSE
3.5    0.67%
Rs. 529.30
 
Days Low
Rs. 518.2
Days High
Rs. 532.2

Open Rs. 529
 
52 week Low
Rs. 329.95
52 week High
Rs.558
 
 
Bid :                 0.00 (0)
Offer :        528.10 (20)
BSE
Rs.528.10
0.6    0.11%
on 21-Jul-2017
BSE
0.6    0.11%
Rs. 528.10
 
Days Low
Rs. 517.7
Days High
Rs. 532.5

Open Rs. 528.4
 
52 week Low
Rs. 328.8
52 week High
Rs.560
 
 
Bid :                 0.00 (0)
Offer :        528.10 (20)
NSE
Rs.529.30
3.5    0.67%
 
 
Last Price (Rs.)  528.10 Value  37091374.00
Net Change (Rs.)  0.60 Best Buy  0.00
Volume  70503 Best Sell  528.10
Prev.Close (Rs.)  527.50 Best Quantity  0
Open (Rs.)  529.00 Sell Quantity  20
High (Rs.)  532.20 52-Week High (Rs.)  558.00
Low (Rs.)  518.20 52-Week Low (Rs.)  329.95
Face Value (Rs.)  1 Market Cap.(Rs/ Mn)  540638.47
 
BSE
You need to upgrade your Flash Player
 
Financial (Rs .in Million)
Balance Sheet
Share Capital1024.00 1024.00 1024.00 
Share Capital1024.00 1024.00 1024.00 
Share Capital1024.00 1024.00 1024.00 
Share Capital1024.00 1024.00 1024.00 
Share Capital1024.00 1024.00 1024.00 
Currents Investments0.00 1009.00 4583.00 
More> 
 
Top 5 PeerCompanies * (Rs .in Million)
Company NameLTP* M.CapBVP/EDiv.Yield
Sun Pharma Inds. 576.60 1383440 86.99 0.00 0.61
Lupin 1142.85 516280 323.33 16.43 0.66
Piramal Enterprises 2916.05 503203 835.79 64.78 0.72
Dr. Reddys Lab 2759.75 457624 694.74 33.06 0.72
Cipla 566.10 455526 158.34 46.71 0.35
 
Mutual Funds Holdings
 
Quarterly Result
(Rs .in millions)Mar 2017Dec 2016Sep 2016
Net Sales8285.0011011.0010914.00
Operating Profit4693.001369.002051.00
PBDT4693.001332.001993.00
Net Profit4714.00539.001090.00
More> 
 
Company News
7/20/2017 12:00:00 AM
Zydus Cadila, Lupin, Welspun Enterprises and Pricol to see some action...
7/20/2017 12:00:00 AM
Zydus Cadila receives final approval from USFDA for Tranexamic Acid In...
7/19/2017 12:00:00 AM
Zydus Cadila launches Mesalamine Delayed Release Tablets in US
More>
 
Ratios
   Earnings Per Share (Rs)6.46 
   Book NAV/Share(Rs)64.63 
   PAT Margin (%)20.21 
   Asset Turnover(x)0.30 
   PER(x)68.57 
   Yield(%)0.72 
   EV/Core EBITDA(x)52.51 
   M Cap / Sales14.05 
   Net Sales Growth(%)-54.06 
   PAT Growth(%)-67.51 
   Total Debt/Equity(x)0.44 
   Current Ratio(x)0.71 
   Quick Ratio(x)0.40 
   Total Debt/Mcap(x)0.06 
More>